Brought to you by 
Seattle Genetics, Millennium sign lymphoma deal
25 Nov 2019
Executive Summary
Four days after losing a major partner for one of its lymphoma projects, Seattle Genetics penned another deal in the space, this time joining forces with Millennium: The Takeda Oncology Co. and its parent Takeda Pharmaceutical to develop SG's brentuximab vedotin (SGN35), in Phase II for relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Takeda comes out of the deal with exclusive rights to sell the compound worldwide, excluding the US and Canada.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seattle Genetics, Millennium sign lymphoma deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice